Skip to content
Announcement:

The results of a recent collaboration between Sanofi, GSK, Lilly, Vesalius Therapeutics, Leiden University, Heidelberg University, ElmorePathology and Newcells aimed at enhancing safety assessments has just been published. Find out how rat kidney gene co-expression networks has enabled biomarker identification and human translation for renal safety assessments.

Find out more

Home › Resources › Videos and webinars › Advancing Radioconjugate Therapeutics: Leveraging Kidney PTC Models for Predictive Uptake and Toxicity Assessment

Advancing Radioconjugate Therapeutics: Leveraging Kidney PTC Models for Predictive Uptake and Toxicity Assessment

Dr Adam Pearson discusses “Advancing Radioconjugate Therapeutics: Leveraging Kidney PTC Models for Predictive Uptake and Toxicity Assessment”.

During the talk, Dr Pearson:

  • Examines the use of in vitro kidney proximal tubule cell (PTC) models to assess renal uptake of radioconjugate therapeutics during early-stage development.
  • Highlights key advancements in PTC model systems, that better replicate renal physiology and transport mechanisms relevant to radioconjugate exposure.
  • Showcases case studies demonstrating how in vitro PTC assays support compound screening and preclinical safety assessment of radioconjugate compounds.

Date: Tuesday 22nd July 2025

Published

July 22, 2025

Share on social media:

Don't miss out on our latest innovations: follow us on Linkedin

View Today

Please enter the required details to view the webinar. You are not automatically signing up for receiving marketing emails.


Get our latest updates straight to your inbox

Book a Call